Methylation markers: A potential force driving cancer diagnostics forward

Oncology Research

Volumn 19, Issue 3-4, 2011, Pages 105-110

  Khandige, Surabhi ^a   Shanbhogue, Vikram V ^b   Chakrabarty, Sanjiban ^a   Kapettu, Satyamoorthy ^a  

^a MANIPAL UNIVERSITY   (India)

^b KASTURBA MEDICAL COLLEGE   (India)

Author keywords

Diagnosis; Epigenetics; Methylation markers; Primary cancer; Prognosis

Indexed keywords

APC PROTEIN; BIOLOGICAL MARKER; CYCLIN D2; GLUTATHIONE TRANSFERASE P1; MULTIDRUG RESISTANCE PROTEIN 1; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; TRANSCRIPTION FACTOR FOXC1; TRANSCRIPTION FACTOR PITX2; TUMOR MARKER;

CANCER DIAGNOSIS; CYTOPATHOLOGY; DNA METHYLATION; EPIGENETICS; GENE EXPRESSION PROFILING; HUMAN; PRIORITY JOURNAL; REVIEW;

EID: 79952423163     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: 10.3727/096504011X12935427587641     Document Type: Review

References (29)

1. Rustin, G. J.; Nelstrop, A. E.; McClean, P.; Brady, M. F.; McGuire, W. P.; Hoskins, W. J.; Mitchell, H.; Lambert, H. E. Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125. J. Clin. Oncol. 14(5):1545-1551; 1996.
2. Kelly, W. K.; Scher, H. I.; Mazumdar, M.; Vlamis, V.; Schwartz, M.; Fossa, S. D. Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. J. Clin. Oncol. 11(4):607-615; 1993.
3. Baselga, J.; Tripathy, D.; Mendelsohn, J.; Baughman, S.; Benz, C. C.; Dantis, L.; Sklarin, N. J.; Seidman, A. D.; Hudis, C. A.; Moore, J.; Rosen, P. P.; Twaddell, T.; Henderson, I. C.; Norton, L. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J. Clin. Oncol. 14(3):737-744; 1996.
4. Baylin, S. B.; Herman, J. G. DNA hypermethylation in tumorigenesis: Epigenetics joins genetics. Trends Genet. 16:168-174; 2000.
5. Bäckdahl, L.; Herberth, M.; Wilson, G.; Tate, P.; Campos, L. S.; Cortese, R.; Eckhardt, F.; Beck, S. Gene body methylation of the dimethylarginine dimethylamino-hydrolase 2 (Ddah2) gene is an epigenetic biomarker for neural stem cell differentiation. Epigenetics 4(4):248-254; 2009.
6. Kim, M. S.; Louwagie, J.; Carvalho, B.; Jochim, S.; Droste, T. S.; Park, H. L.; Chae, Y. K.; Yamashita, K.; Liu, J.; Ostrow, K. L.; Ling, S.; Preston, R. G.; Demokan, S.; Yalniz, Z.; Dalay, N.; Meijer, G. A.; Criekinge, W. V.; Sidransky, D. Promoter DNA methylation of oncostatin M receptor-β as a novel diagnostic and therapeutic marker in colon cancer. PLoS One 4(8):e6555; 2009.
7. Ongenaert, M.; Wisman, G. B.; Volders, H. H.; Koning, A. J.; Zee, A. G.; Criekinge, W. V.; Schuuring, E. Discovery of DNA methylation markers in cervical cancer using relaxation ranking. BMC Med. Genomics 24(1):57; 2008.
8. Costa, V. L.; Henrique, R.; Jerónimo, C. Epigenetic markers for molecular detection of prostate cancer. Dis. Markers 23(1-2):31-41; 2007.
9. Kron, K. J.; Liu, L.; Pethe, V. V.; Demetrashvili, N.; Nesbitt, M. E.; Trachtenberg, J.; Ozcelik, H.; Fleshner, N. E.; Briollais, L.; van der Kwast, T. H.; Bapat, B. DNA methylation of HOXD3 as a marker of prostate cancer progression. Lab. Invest. 90:1060-1067; 2010.
10. Jiang, S. W.; Li, J.; Podratz, K.; Dowdy, S. Application of DNA methylation biomarkers for endometrial cancer management. Expert Rev. Mol. Diagn. 8(5):607-616; 2008.
11. Vargas, H. H.; Lambert, M. P.; Kelm, F. L. C.; Gouysse, G.; Chopin, S. M.; Tavtigian, S. V.; Scoazec, J. Y.; Herceg, Z. Hepatocellular carcinoma displays distinct DNA methylation signatures with potential as clinical predictors. PLoS One 5(3):e9749; 2010.
12. Wang, M. X.; Wang, H. Y.; Zhao, X.; Srilatha, N.; Zheng, D.; Shi, H.; Ning, J.; Duff, D. J.; Taylor, K. H.; Gruner, B. A.; Caldwell, C. W. Molecular detection of B-cell neoplasms by specific DNA methylation biomarkers. Int. J. Clin. Exp. Pathol. 3(3):265-279; 2010.
13. Euhus, D. M.; Bu, D.; Milchgrub, S.; Xie, X.-J.; Bian, A.; Leitch, A. M.; Lewis, C. M. DNA methylation in benign breast epithelium in relation to age and breast cancer risk. Cancer Epidemiol. Biomarkers Prev. 17(5):1051-1059; 2008.
14. Hartmann, O.; Spyratos, F.; Harbeck, N.; Dietrich, D.; Fassbender, A.; Schmitt, M.; Eppenberger-Castori, S.; Vuaroqueaux, V.; Lerebours, F.; Welzel, K.; Maier, S.; Plum, A.; Niemann, S.; Foekens, J. A.; Lesche, R.; Martens, J. W. M. DNA methylation markers predict outcome in node-positive, estrogen receptor-positive breast cancer with adjuvant anthracycline-based chemotherapy. Clin. Cancer Res. 15:315-323; 2009.
15. Schatz, P.; Dietrich, D.; Koenig, T.; Burger, M.; Lukas, A.; Fuhrmann, I.; Kristiansen, G.; Stoehr, R.; Schuster, M.; Lesche, R.; Weiss, G.; Corman, J.; Hartmann, A. Development of a diagnostic microarray assay to assess the risk of recurrence of prostate cancer based on PITX2 DNA methylation. J. Mol. Diagn. 12(3):345-353; 2010.
16. Chung, W.; Kwabi-Addo, B.; Ittmann, M.; Jelinek, J.; Shen, L.; Yu, Y.; Issa, J. P. Identification of novel tumor markers in prostate, colon and breast cancer by unbiased methylation profiling. PLoS One 3(4):e2079; 2008.
17. Shapiro, B.; Chakrabarty, M.; Cohn, E. M.; Leon, S. A. Determination of circulating DNA levels in patients with benign or malignant gastrointestinal disease. Cancer 51(11):2116-2120; 1983.
18. Leon, S. A.; Ehrlich, G. E.; Shapiro, B.; Labbate, V. A. Free DNA in the serum of rheumatoid arthritis patients. J. Rheumatol. 4(2):139-143; 1977.
19. Fiegl, H.; Millinger, S.; Mueller-Holzner, E.; et al. Circulating tumor-specific DNA: A marker for monitoring efficacy of adjuvant therapy in cancer patients. Cancer Res. 65(4):1141-1145; 2005.
20. Skvortsova, T. E.; Rykova, E. Y.; Tamkovich, S. N.; et al. Cell-free and cell-bound circulating DNA in breast tumours: DNA quantification and analysis of tumour-related gene methylation. Br. J. Cancer 94(10):1492-1495; 2006.
21. Wallner, M.; Herbst, A.; Behrens, A.; Crispin, A.; Stieber, P.; Göke, B.; Lamerz, R.; Kolligs, F. T. Methylation of serum DNA is an independent prognostic marker in colorectal cancer. Clin. Cancer Res. 12(24):7347-5732; 2006.
22. Ellinger, J.; El Kassem, N.; Heukamp, L. C.; Matthewsa, S.; Cubukluoz, F.; Kahl, P.; Perabo, F. G.; Müller, S. C.; von Ruecker, A.; Bastian, P. J. Hypermethylation of cell-free serum DNA indicates worse outcome in patients with bladder cancer. J. Urol. 179(1):346-352; 2008.
23. Fiegl, H.; Mueller, H. M.; Widschwendter, A.; Ivarsson, L.; Goebel, G.; Perkmann, E.; Marth, C.; Widschwendter, M. P13 DNA methylation in serum of breast cancer patients: An independent prognostic marker. Eur. J. Cancer Suppl. 2(1):44; 2004.
24. Fujiwara, K.; Fujimoto, N.; Tabata, M.; Nishii, K.; Matsuo, K.; Hotta, K.; Kozuki, T.; Aoe, M.; Kiura, K.; Ueoka, H.; Tanimoto, M. Identification of epigenetic aberrant promoter methylation in serum DNA is useful for early detection of lung cancer. Clin. Cancer Res. 11(3): 1219-1225; 2005.
25. Ellinger, J.; Albers, P.; Perabo, F. G.; Muller, S. C.; von Ruecker, A.; Bastian, P. J. CpG island hypermethylation of cell-free circulating serum DNA in patients with testicular cancer. J. Urol. 182(1):324-329; 2009.
26. Dejeux, E.; Ronneberg, J. A.; Solvang, H.; Bukholm, I.; Geisler, S.; Aas, T.; Gut, I. G.; Borresen-Dale, A. L.; Lonning, P. E.; Kristensen, V. N.; Tost, J. DNA methylation profiling in doxorubicin treated primary locally advanced breast tumours identifies novel genes associated with survival and treatment response. Mol. Cancer 9(1):68; 2010.
27. Attaleb, M.; El hamadani, W.; Khyatti, M.; Benbacer, L.; Benchekroun, N.; Benider, A.; Amrani, M.; El Mzibri, M. Status of p16(INK4a) and E-cadherin gene promoter methylation in Moroccan patients with cervical carcinoma. Oncol. Res. 18(4):185-192; 2009.
28. Rasti, M.; Tavasoli, P.; Monabati, A.; Entezam, M. Association between HIC1 and RASSF1A promoter hypermethylation with MTHFD1 G1958A polymorphism and clinicopathological features of breast cancer in Iranian patients. Iran Biomed. J. 13(4):133-140; 2009.
29. Niklinska, W.; Naumnik, W.; Sulewska, A.; Koz?owski, M.; Pankiewicz, W.; Milewski, R. Prognostic significance of DAPK and RASSF1A promoter hypermethylation in non-small cell lung cancer (NSCLC). Folia Histochem. Cytobiol. 47(2):275-280; 2009.